News
BTX
0.5750
-4.07%
-0.0244
BRIEF-Brooklyn ImmunoTherapeutics - Announces Receipt Of Nasdaq Notification Regarding Minimum Bid Price Deficiency
reuters.com · 06/17 21:30
Brooklyn ImmunoTherapeutics receives non-compliance letter from Nasdaq
Brooklyn ImmunoTherapeutics (NASDAQ:BTX) said it had received a notice from the Nasdaq stating that it was not in compliance with the minimum bid price requirement of US$1.00 per share under
Seekingalpha · 06/17 21:09
Brooklyn ImmunoTherapeutics names new Interim CEO, CFO
Brooklyn ImmunoTherapeutics (NASDAQ:BTX) on Monday has announced the appointment of Matt Angel as its interim chief executive officer and president.  He will replace current CEO and President Howard J. Federoff, who departs to focus
Seekingalpha · 05/31 11:53
BRIEF-Brooklyn ImmunoTherapeutics Announces Changes To Executive Management 
reuters.com · 05/31 11:48
Brooklyn ImmunoTherapeutics Appoints Matt Angel As Interim CEO And President, Appoints Andrew Jackson CFO
Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the
Benzinga · 05/31 11:37
BRIEF-Brooklyn Immunotherapeutics Announces Receipt Of Notice From Nasdaq
reuters.com · 05/27 20:39
Brooklyn ImmunoTherapeutics Announces Receipt Of Notice From Nasdaq Regarding Delayed Filing Of Quarterly Report On Form 10-Q
 Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with
Benzinga · 05/27 20:34
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q
SAN DIEGO, May 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, bloo...
GlobeNewswire · 05/27 20:30
Amarin Announces Appointment of New Directors and Board Leadership Changes
Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company’s Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Ac...
GlobeNewswire · 05/19 12:23
BRIEF-Brooklyn Immunotherapeutics Inc Files For Offering Of Up To 13.7 Shares Of Common Stock By The Selling Stockholder - SEC Filing
reuters.com · 04/29 20:37
Brooklyn ImmunoTherapeutics stock rises ~7% on setting up of new R&D facility
Brooklyn ImmunoTherapeutics (NASDAQ:BTX) said it has set up a new corporate and research and development facility at The Boardwalk at Science Center Drive in San Diego, California to support translational
Seekingalpha · 04/21 12:56
Brooklyn ImmunoTherapeutics Announces Establishment Of New Research And Development Facility For Advancement Of Engineered Cellular Medicines
Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating
Benzinga · 04/21 11:33
Brooklyn ImmunoTherapeutics stock down ~12% after Q4 2021 results
Shares of Brooklyn ImmunoTherapeutics (NASDAQ:BTX) have fallen 11.9% on Monday in afternoon trading, after the clinical-stage biopharmaceutical company reported on April 15 its Q4 and FY 2021 results. BTX stock
Seekingalpha · 04/18 18:03
Brooklyn ImmunoTherapeutics Shares Slide After Company Reports Q4 Loss
MT Newswires · 04/18 15:24
Brooklyn Immunotherapeutics GAAP EPS of -$0.16
Brooklyn Immunotherapeutics press release (NASDAQ:BTX): Q4 GAAP EPS of -$0.16. As of December 31, 2021, Brooklyn had ~$17.0M in cash, compared to $1.6M as of December 31, 2020.
Seekingalpha · 04/18 07:58
BRIEF-Brooklyn Immunotherapeutics Announces Closing Of $12 Mln Private Placement
reuters.com · 03/09 21:23
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blo...
GlobeNewswire · 03/09 21:15
Brooklyn ImmunoTherapeutics slides after $12M equity offering
Brooklyn ImmunoTherapeutics (NASDAQ:BTX) has announced a $12M private placement agreement with a healthcare investor. Under the agreement, Brooklyn will issue 6,857,142 units priced at $1.75 each. Each unit consists of
Seekingalpha · 03/07 13:24
BRIEF-Brooklyn Immunotherapeutics Announces $12 Mln Private Placement
reuters.com · 03/07 13:06
BRIEF-Brooklyn Immunotherapeutics Inc - Expanded Board Size From Five To Six Directors
reuters.com · 01/20 12:49
More
Webull provides a variety of real-time BTX stock news. You can receive the latest news about Brooklyn Immunotherapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About BTX
Brooklyn ImmunoTherapeutics, Inc. (Brooklyn), formerly NTN Buzztime, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on cytokine-based therapies in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Brooklyn is engaged in developing IRX-2, a cytokine-based therapy, to treat patients with head and neck cancer. IRX-2 is an allogeneic, reproducible, primary, human cell-derived Interleukin-2 (IL-2) therapeutic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. In addition to IL-2, IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as an injection around lymph node beds.